Int J Infect Dis . Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach

[tetano]

Int J Infect Dis


. 2021 Apr 23;S1201-9712(21)00380-5.
doi: 10.1016/j.ijid.2021.04.068. Online ahead of print.
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach


Alessandra D'Abramo[SUP] 1 [/SUP], Serena Vita[SUP] 1 [/SUP], Gaetano Maffongelli[SUP] 2 [/SUP], Andrea Mariano[SUP] 1 [/SUP], Chiara Agrati[SUP] 1 [/SUP], Concetta Castilletti[SUP] 1 [/SUP], Delia Goletti[SUP] 1 [/SUP], Giuseppe Ippolito[SUP] 1 [/SUP], Emanuele Nicastri[SUP] 1 [/SUP], Spallanzani COVID-19 Case Investigation Team



Affiliations

• PMID: 33901654
• DOI: 10.1016/j.ijid.2021.04.068

Abstract

Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response causing severe manifestations during COronaVIrus Disease-2019. The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins were reported.

Keywords: Anti-CD20 therapy; B-cell depletion; SARS-CoV-2 infection; prolonged infection.